Enovis Corporation/$ENOV
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Enovis Corporation
Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.
Ticker
$ENOV
Sector
Primary listing
NYSE
Employees
7,367
Headquarters
Website
ENOV Metrics
BasicAdvanced
$1.8B
-
-$24.09
1.65
-
Price and volume
Market cap
$1.8B
Beta
1.65
52-week high
$49.38
52-week low
$25.47
Average daily volume
776K
Financial strength
Current ratio
2.225
Quick ratio
0.809
Long term debt to equity
69.044
Total debt to equity
71.22
Interest coverage (TTM)
0.90%
Profitability
EBITDA (TTM)
369.047
Gross margin (TTM)
60.57%
Net profit margin (TTM)
-61.22%
Operating margin (TTM)
3.46%
Effective tax rate (TTM)
-3.24%
Revenue per employee (TTM)
$300,000
Management effectiveness
Return on assets (TTM)
0.97%
Return on equity (TTM)
-51.02%
Valuation
Price to revenue (TTM)
0.794
Price to book
0.88
Price to tangible book (TTM)
-3.73
Price to free cash flow (TTM)
77.875
Free cash flow yield (TTM)
1.28%
Free cash flow per share (TTM)
0.401
Growth
Revenue change (TTM)
11.57%
Earnings per share change (TTM)
1,007.17%
3-year revenue growth (CAGR)
12.86%
10-year revenue growth (CAGR)
-5.92%
3-year earnings per share growth (CAGR)
281.55%
10-year earnings per share growth (CAGR)
17.26%
Bulls say / Bears say
Enovis achieved 9% year-over-year revenue growth in Q3, with net sales of $549 million topping consensus expectations of $538.61 million (Nasdaq)
The Reconstructive segment delivered 12% reported (9% organic) growth in Q3, fueled by strong extremities performance and international expansion (Nasdaq)
Management increased full-year 2025 adjusted EBITDA guidance to $395–405 million and adjusted EPS guidance to $3.10–3.25, underscoring confidence in sustained operational execution (Nasdaq)
A non-cash goodwill impairment charge of $548 million in Q3 led to a GAAP net loss of $571 million, significantly reducing reported profitability (Nasdaq)
Despite beating earnings forecasts, Enovis shares declined 3.6% after the Q3 release, reflecting investor concerns about the significant impairment charge and future earnings quality (Investing.com)
The Prevention & Recovery segment posted just 4% organic growth in Q3, lagging the Reconstructive segment and highlighting slower progress in its main bracing products (Nasdaq)
Data summarised monthly by Lightyear AI. Last updated on 11 Nov 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Enovis Corporation stock?
Enovis Corporation (ENOV) has a market cap of $1.8B as of November 14, 2025.
What is the P/E ratio for Enovis Corporation stock?
The price to earnings (P/E) ratio for Enovis Corporation (ENOV) stock is 0 as of November 14, 2025.
Does Enovis Corporation stock pay dividends?
No, Enovis Corporation (ENOV) stock does not pay dividends to its shareholders as of November 14, 2025.
When is the next Enovis Corporation dividend payment date?
Enovis Corporation (ENOV) stock does not pay dividends to its shareholders.
What is the beta indicator for Enovis Corporation?
Enovis Corporation (ENOV) has a beta rating of 1.65. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.